Aligos Therapeutics

ALG-000184 has a new name!     We are happy to announce that the United States Adopted Names Council has adopted “pevifoscorvir sodium” as the nonprorietary name for our lead candidate, ALG-000184.     Pevifoscorvir sodium is a capsid assembly modulator (CAM-E) designed to exploit the dual role of CAMs.     Learn more here: https://lnkd.in/gw-Acb9w

Join us for the Aligos fireside chat with analyst Patrick R. Trucchio at the H.C. Wainwright & Co., LLC Liver Disease Virtual Conference, this October 21-22. Tune in to the webcast: https://lnkd.in/gkcMseYG #HCWainwright #LiverDisease 

It’s official! We are presenting at The Liver Meeting, hosted by the American Association for the Study of Liver Diseases (AASLD), happening November 7-11 in Washington D.C. Dr. Man-Fung Yuen, MBBS, MD, PhD, DSc, will present data demonstrating potent #HBV DNA suppression with our investigational oral once-daily capsid assembly modulator. For those attending, join us for the oral presentation on November 9th during the 5:00 p.m. - 6:30 p.m. ET session. https://lnkd.in/ezsbEsbn #AASLD25 #TheLiverMeeting

#HBV does not discriminate. It can infect anyone – regardless of age, race, or gender – with an estimated 254 million people living with chronic #HBV infection. However, certain demographics are at a higher risk of contracting the virus. Learn more about some of these groups in the infographic below.    For more information about chronic HBV infection and our approach to treating it, visit our website: https://lnkd.in/g84Nwx6A 

Lawrence M. Blatt, CEO of Aligos, recently joined host Mike Hennessy Jr. on the Pharmaceutical Executive’s Profiles in Medicine podcast to share how his journey spearheading biotech companies has shaped his leadership philosophy at Aligos. He shares advice for future biotech leaders, grounded in his guiding principle: “Do what’s right for the patients, the rest will follow.” His leadership approach also emphasizes hiring smart people and trusting their expertise. For more insights from Lawrence, listen here: https://lnkd.in/ePKVBnRQ 

We were proud to showcase our preclinical progress at the 2025 International HBV Meeting hosted by the Hepatitis B Foundation this year in Berlin!     Our team delivered six presentations demonstrating our continued innovation in liver and viral diseases.     Key updates included:  • Preclinical data showing our lead chronic #HBV therapeutic candidate reduces HBV cccDNA  • Expansion of our pipeline to include a discovery stage ASO program for the treatment of hepatitis delta virus (HDV).  

We are excited to share that our work on novel protease inhibitors has been featured in the latest Pharmaron newsletter! Check out the September 2025 edition and see the link to our J. Med. Chem. article on ALG-097558. #Aligos #DrugDiscovery #Innovation #ScientificResearch

Our team is presenting at the H.C. Wainwright 27th annual Global Investment Conference, being held September 8-10th in New York City.      Tune in as we discuss our purpose-built pipeline, advancing therapeutics for high unmet medical needs including chronic hepatitis B virus #HBV infection and #MASH: https://lnkd.in/gkcMseYG 

The #MASH market is evolving.   Our CEO, Lawrence M. Blatt, recently spoke with Joseph Haas about the current landscape of metabolic dysfunction-associated steatohepatitis (MASH) therapies – and how the future of treatment requires a holistic approach.    Read the article here: https://lnkd.in/gFmKREdm

We’re pleased to share some exciting news this week for patients with #MASH! The possible implementation of non-invasive surrogate endpoints has the potential to significantly enhance the efficiency of bringing next-generation therapies to those in need. This development is a promising step towards more accessible & effective treatment options and aligns with our mission of improving patient outcomes through the development of best-in-class therapies for liver diseases. Learn more below: